Merrimack Cash End of Year vs Cash Beginning of Year Analysis

MACK Stock  USD 14.77  0.02  0.14%   
Trend analysis of Merrimack Pharmaceuticals balance sheet accounts such as Other Current Liab of 348.6 K provides information on Merrimack Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Merrimack Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Merrimack Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.

About Merrimack Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Merrimack Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Merrimack Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Merrimack Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Merrimack currently owns. An asset can also be divided into two categories, current and non-current.

Merrimack Pharmaceuticals Balance Sheet Chart

Merrimack Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Merrimack Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Merrimack Pharmaceuticals' Total Stockholder Equity is quite stable compared to the past year. Common Stock Total Equity is expected to rise to about 1.8 M this year, although the value of Short and Long Term Debt Total will most likely fall to about 16.2 M.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Merrimack Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Merrimack Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Merrimack Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merrimack Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.Tax Provision is expected to rise to about 12.6 K this year, although the value of Selling General Administrative will most likely fall to about 2.1 M.
 2023 2024 (projected)
Total Operating Expenses2.2M2.1M
Cost Of Revenue400.5K380.5K

Merrimack Pharmaceuticals fundamental ratios Correlations

-0.330.04-0.57-0.50.49-0.20.650.13-0.53-0.39-0.22-0.450.14-0.29-0.79-0.49-0.310.79-0.52-0.2-0.30.08-0.78-0.750.2
-0.330.660.670.76-0.340.83-0.020.34-0.220.430.790.920.270.98-0.050.640.680.010.710.831.00.54-0.050.690.09
0.040.660.540.76-0.50.930.370.84-0.820.10.580.66-0.110.57-0.190.60.340.430.680.930.650.76-0.190.320.42
-0.570.670.540.87-0.610.74-0.110.42-0.11-0.050.450.78-0.060.610.430.670.31-0.270.760.740.630.210.430.650.17
-0.50.760.760.87-0.670.890.110.61-0.350.210.560.86-0.050.660.30.740.43-0.090.840.890.720.470.30.640.27
0.49-0.34-0.5-0.61-0.67-0.60.22-0.440.15-0.1-0.33-0.570.38-0.19-0.26-0.93-0.450.47-0.91-0.6-0.29-0.32-0.26-0.68-0.21
-0.20.830.930.740.89-0.60.220.69-0.590.170.720.86-0.020.75-0.050.750.470.170.831.00.810.69-0.050.560.32
0.65-0.020.37-0.110.110.220.220.35-0.63-0.380.08-0.090.060.02-0.4-0.26-0.320.71-0.180.220.00.41-0.4-0.570.14
0.130.340.840.420.61-0.440.690.35-0.860.060.060.39-0.310.21-0.250.420.260.490.490.690.320.38-0.250.160.5
-0.53-0.22-0.82-0.11-0.350.15-0.59-0.63-0.860.12-0.16-0.20.11-0.140.51-0.16-0.02-0.79-0.22-0.59-0.22-0.540.510.2-0.53
-0.390.430.1-0.050.21-0.10.17-0.380.060.120.170.390.170.38-0.070.270.71-0.150.270.170.430.03-0.070.580.0
-0.220.790.580.450.56-0.330.720.080.06-0.160.170.730.270.790.070.570.34-0.040.60.720.780.810.070.450.03
-0.450.920.660.780.86-0.570.86-0.090.39-0.20.390.730.30.830.120.780.66-0.140.840.860.890.440.120.740.34
0.140.27-0.11-0.06-0.050.38-0.020.06-0.310.110.170.270.30.28-0.11-0.20.10.17-0.17-0.020.25-0.08-0.11-0.140.46
-0.290.980.570.610.66-0.190.750.020.21-0.140.380.790.830.28-0.050.510.60.030.580.750.990.53-0.060.62-0.07
-0.79-0.05-0.190.430.3-0.26-0.05-0.4-0.250.51-0.070.070.12-0.11-0.050.13-0.25-0.630.18-0.05-0.08-0.121.00.26-0.1
-0.490.640.60.670.74-0.930.75-0.260.42-0.160.270.570.78-0.20.510.130.67-0.410.980.750.60.450.130.830.17
-0.310.680.340.310.43-0.450.47-0.320.26-0.020.710.340.660.10.6-0.250.67-0.220.640.470.670.18-0.250.780.04
0.790.010.43-0.27-0.090.470.170.710.49-0.79-0.15-0.04-0.140.170.03-0.63-0.41-0.22-0.350.170.050.29-0.63-0.580.36
-0.520.710.680.760.84-0.910.83-0.180.49-0.220.270.60.84-0.170.580.180.980.64-0.350.830.670.480.180.820.2
-0.20.830.930.740.89-0.61.00.220.69-0.590.170.720.86-0.020.75-0.050.750.470.170.830.810.69-0.050.560.32
-0.31.00.650.630.72-0.290.810.00.32-0.220.430.780.890.250.99-0.080.60.670.050.670.810.55-0.080.670.04
0.080.540.760.210.47-0.320.690.410.38-0.540.030.810.44-0.080.53-0.120.450.180.290.480.690.55-0.120.160.04
-0.78-0.05-0.190.430.3-0.26-0.05-0.4-0.250.51-0.070.070.12-0.11-0.061.00.13-0.25-0.630.18-0.05-0.08-0.120.26-0.1
-0.750.690.320.650.64-0.680.56-0.570.160.20.580.450.74-0.140.620.260.830.78-0.580.820.560.670.160.26-0.11
0.20.090.420.170.27-0.210.320.140.5-0.530.00.030.340.46-0.07-0.10.170.040.360.20.320.040.04-0.1-0.11
Click cells to compare fundamentals

Merrimack Pharmaceuticals Account Relationship Matchups

Merrimack Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding13.4M13.4M13.4M13.5M14.3M10.9M
Total Assets20.1M16.8M14.7M19.8M19.2M18.2M
Other Current Liab2.5M647K442K401K367K348.7K
Total Current Liabilities2.8M770K562K589K441K419.0K
Total Stockholder Equity17.3M16.0M14.2M19.2M18.7M19.7M
Net Debt(16.6M)(14.0M)(14.2M)(19.4M)(6.0M)(5.7M)
Retained Earnings(540.6M)(543.6M)(546.1M)(547.6M)(548.8M)(576.3M)
Accounts Payable271K123K120K188K74K70.3K
Cash16.6M14.0M14.2M19.4M6.0M5.7M
Non Current Assets Total1.4M232K66K8K4K3.8K
Non Currrent Assets Other1.4M232K66K8K4K3.8K
Cash And Short Term Investments16.6M14.0M14.2M19.4M18.9M17.9M
Liabilities And Stockholders Equity20.1M16.8M14.7M19.8M19.2M18.2M
Non Current Liabilities Total14.9M271K123K120K589K0.0
Other Current Assets2.1M2.5M480K389K309K293.6K
Other Stockholder Equity556.6M558.3M558.9M565.5M566.2M507.8M
Total Liab2.8M770K562K589K441K419.0K
Total Current Assets18.7M16.5M14.7M19.8M19.2M18.2M
Other Assets2.7M1.4M232K66K8K0.0
Net Tangible Assets17.3M16.0M14.2M19.2M22.1M23.2M
Retained Earnings Total Equity(523.3M)(540.6M)(543.6M)(547.6M)(492.9M)(517.5M)
Capital Surpluse580.8M556.6M558.3M565.5M650.4M625.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merrimack Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merrimack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merrimack Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Merrimack Pharmaceuticals Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.
Note that the Merrimack Pharmaceuticals information on this page should be used as a complementary analysis to other Merrimack Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Merrimack Stock analysis

When running Merrimack Pharmaceuticals' price analysis, check to measure Merrimack Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merrimack Pharmaceuticals is operating at the current time. Most of Merrimack Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Merrimack Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merrimack Pharmaceuticals' price. Additionally, you may evaluate how the addition of Merrimack Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
CEOs Directory
Screen CEOs from public companies around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is Merrimack Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merrimack Pharmaceuticals. If investors know Merrimack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merrimack Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.08)
Return On Assets
(0.07)
Return On Equity
(0.06)
The market value of Merrimack Pharmaceuticals is measured differently than its book value, which is the value of Merrimack that is recorded on the company's balance sheet. Investors also form their own opinion of Merrimack Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Merrimack Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merrimack Pharmaceuticals' market value can be influenced by many factors that don't directly affect Merrimack Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merrimack Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Merrimack Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merrimack Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.